Showing results (401-410 of 523) with videos related to
Sort By:
Pageof 53
Future Oncology (London, England)|March 6, 2023
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumorsMisako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.Cancers|August 7, 2021
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient TumorsEdouard Auclin, Perrine Vuagnat, Cristina Smolenschi, et al.JCO Precision Oncology|October 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine OncologyPatricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, et al.Lung Cancer (Amsterdam, Netherlands)|May 24, 2022
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcomeAlice Mogenet, Fabrice Barlesi, Benjamin Besse, et al.The Journal of Liquid Biopsy|March 3, 2025
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experienceClaudia Parisi, José Carlos Benitez, Hélène Lecourt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialPasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.Science Advances|November 8, 2023
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLCMarie Naigeon, Matthieu Roulleaux Dugage, François-Xavier Danlos, et al.European Journal of Cancer (Oxford, England : 1990)|December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC networkArthur Petat, Eric Dansin, Fabien Calcagno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung CancerKathryn C Arbour, Laura Mezquita, Niamh Long, et al.The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.Pageof 53